Systemic tacrolimus (FK 506) is effective for the treatment of psoriasis in a double-blind, placebo-controlled study. The European FK 506 Multicentre Psoriasis Study Group (Q71077355)
Jump to navigation
Jump to search
scientific article published on 01 April 1996
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | Systemic tacrolimus (FK 506) is effective for the treatment of psoriasis in a double-blind, placebo-controlled study. The European FK 506 Multicentre Psoriasis Study Group |
scientific article published on 01 April 1996 |
Statements
Systemic tacrolimus (FK 506) is effective for the treatment of psoriasis in a double-blind, placebo-controlled study. The European FK 506 Multicentre Psoriasis Study Group (English)